Analysis Tools
mortality/aging
|
• mutants become ill shortly after pIpC treatment and exhibit lethargy, ruffling of fur, and hunched posture and die from leukemia
|
hematopoietic system
|
• mice treated with pIpC to induce Cre expression exhibit an enlarged thymus
|
|
• 10-fold increase in spleen cellularity after pIpC administration to induce Cre expression
|
|
• increase in blast cell frequency after pIpC administration to induce Cre expression
|
|
• mice treated with polyinosine-polycytidine (pIpC) to induce Cre expression exhibit extramedullary hematopoiesis, with prominent expansion in the number of immature myeloid cells
• mice develop myeloproliferative disease shortly after pIpC administration to induce Cre expression with complete effacement of the splenic architecture
|
|
• reduction in bone marrow cellularity after pIpC administration to induce Cre expression
|
|
• mice treated with pIpC to induce Cre expression exhibit an increase in hematopoietic stem cell proliferation but become depleted, most likely due to inhibition of self-renewal as no increase in cell death was observed
• mutants maintained on rapamycin after pIpC treatment do not exhibit expansion of hematopoietic stem cells
|
immune system
|
• mice treated with pIpC to induce Cre expression exhibit an enlarged thymus
|
|
• 10-fold increase in spleen cellularity after pIpC administration to induce Cre expression
|
neoplasm
|
• within 4-6 weeks after pIpC treatment, most mutants progress to leukemia, including acute myeloid leukemia and acute lymphoblastic leukemia
• mutants maintained on rapamycin after pIpC treatment do not develop leukemia
|
|
• seen in mutants within 4-6 weeks after pIpC treatment
|
|
• seen in mutants within 4-6 weeks after pIpC treatment
|
endocrine/exocrine glands
|
• mice treated with pIpC to induce Cre expression exhibit an enlarged thymus
|
growth/size/body
|
• 10-fold increase in spleen cellularity after pIpC administration to induce Cre expression
|
